Combined MIGS and cataract surgery option offers positive results

Ophthalmology Times EuropeOphthalmology Times Europe July/August 2021
Volume 17
Issue 06

Retrospective review highlights the sustained efficacy of combination procedure.

MIGS and cataract surgery option offers positive results

Reviewed by Dr Karsten Klabe.

Results from 5 years of follow-up show that minimally invasive glaucoma surgery (MIGS) with simultaneous implantation of two trabecular microbypass stents (iStent Inject, Glaukos) combined with phacoemulsification is safe and provides durable moderate lowering of intraocular pressure (IOP). It also reduces the burden of topical ocular hypotensive medications, according to Dr Karsten Klabe.

Dr Karsten Klabe

Dr Karsten Klabe

Dr Klabe is in private practice at the Breyer, Kaymak and Klabe Eye Surgery Practice in Düsseldorf, Germany, and is a partner at the International Vision Correction Research Centre of the Heidelberg University Hospital. “A number of MIGS procedures are now available, and [although] they have shown encouraging initial results in pre-marketing clinical trials, data are needed to understand their long-term efficacy and safety,” said Dr Klabe.

Related: Personalising glaucoma surgery: The role of MIGS

“Our experience using combined iStent Inject implantation and cataract surgery shows that with selection of appropriate candidates, patients will rarely need further intervention for their glaucoma, and the majority can become medication-free,” he said. “Considering the latter benefit, adding the iStent Inject when patients need cataract surgery addresses the adherence issues we face when prescribing glaucoma therapies and their potential to cause ocular surface disease so that patients have a higher quality of life.”

Dr Klabe’s study of outcomes after combined cataract surgery with implantation of the iStent Inject was a retrospective review that included 164 eyes in 103 patients. The cohort had a mean age of 75.4 years and the majority were male. Primary open-angle glaucoma was the predominant diagnosis (82%) and the remaining eyes had pseudoexfoliation glaucoma (18%).

Related: Eliminating the potential land mines in glaucoma surgery

Preoperatively, the 164 eyes had a mean IOP with medication of 18.5 mmHg. The average mean deviation on the visual field was -6.19 dB MD and mean cup/disc ratio was 0.59.

Twenty-nine eyes (18%) had previously been treated with selective laser trabeculoplasty (SLT), and eight eyes had undergone previous surgery, which included placement of the Xen Gel Stent (Allergan), canaloplasty, trabeculectomy or iridotomy. All of the previous interventions were performed more than 3 months prior to the combination cataract/MIGS procedure.

Related: Endoscopic cyclophotocoagulation adds cumulative advantage to MIGS

Of the 164 implanted eyes, 157 had 24 months of follow-up; 129, 85 and 61 eyes were seen at 26, 48 and 60 months, respectively. Mean IOP decreased to 16 mmHg at 1 month after surgery and to 15.5 mmHg at month 6, and stabilised at that level (±0.5 mmHg) for the remaining follow-up duration.

At baseline, patients were taking a mean of 1.47 medications to lower IOP (range 0–4). Throughout follow-up, no patients were taking more than two medications and the mean of medications used daily ranged from 0.17 to 0.23 without any evidence of an increase over time.

Safety highlights

MIGS and cataract surgery option offers positive results

The two microstents are injected into the eye using a specially designed applicator. (Image courtesy of Dr Karsten Klabe)

Highlighting the safety of the combination procedure, Dr Klabe reported that there were very few complications in the series. The majority were minor and related to the MIGS procedure. They included hyphaema in 11 eyes (6.7%), persistent hypotony (IOP < 10 mmHg for more than 1 month) in two eyes (1.2%) and iris incarceration in two eyes (1.2%). In addition, there were seven cases (4.3%) of stent occlusion.

“The cases of occlusion were observed later than 3 months after surgery and were related to implantation that was too deep,” Dr Klabe said. “It is very important to hold the injector in place without pushing it forwards during implantation. However, the introduction of the iStent [inject] with a wider flange solved the risk of over-implantation.”

Related: Study examines pairing phacoemulsification with implantation of stents

Data regarding the need for further glaucoma surgery provided further evidence of the efficacy of the combination surgery. Over the 5 years of follow-up, only seven eyes (4.3%) underwent a second procedure: placement of the Xen Gel Stent in three eyes, implantation of the Preserflo MicroShunt (Santen) in two eyes, SLT in one eye and cyclophotocoagulation in one eye.

Surgical technique

The two microstents are pre-loaded in a specially designed applicator in a procedure that has a short learning curve but requires minimal additional settings and instruments, according to Dr Klabe. “When combined with phacoemulsification, the glaucoma portion of the procedure can be done either prior to or after the cataract surgery, according to the surgeon’s preference,” he said.

Related: SMILE procedure offers low enhancement rate after nomogram adjustment

Dr Klabe explained that he prefers to perform the stent implantation at the end of the surgery, noting that the deep anterior chamber offers excellent visibility and lowers the risk of iris damage. “On the other hand, the main incision in my cases is only 2.2 mm and prevents the loss of [the] ophthalmic viscosurgical device and flattening of the anterior chamber,” he said. “Use of a Vold Gonioprism (Volk Optical) with retention ring may be helpful because of the low pressure on the cornea that guarantees good visibility.”

Karsten Klabe, MD
Dr Klabe is a consultant/adviser to, study investigator for and recipient of travel stipends from Glaukos and other companies that market devices for MIGS.

Related Content: Cataract & Refractive | Glaucoma | Retina

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.